Brief: Australian Clinical Labs Responds To Healius' Target's Statement
May 22 (Reuters) - Australian Clinical Labs Ltd
ACL.AX :
* RESPONSE TO HEALIUS' TARGET'S STATEMENT
* OFFERED MEETING WITH HEALIUS BOARD TO DISCUSS THE
RATIONALE FOR
OFFER, BUT HEALIUS BOARD DECLINED TO TAKE UP OFFER
* CONTINUES TO BELIEVE PROPOSED MERGER REPRESENTS MOST VALUE
ACCRETIVE OPTION TO HEALIUS SHAREHOLDERS
Source text for Eikon: ID:nASXbYJsX8
Further company coverage: ACL.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Australian Clinical Labs
See all newsBrief: Australian Clinical Labs Appoints Deloitte As Auditor
Australia's Optiscan rises after imaging more than 80 cases in ACL study
Australian Clinical Labs falls to over two-week low on trading ex-dividend
Australian Clinical Labs at 6-month high on upbeat full-year results, guidance
Brief: Australian Clinical Labs Says It Expects FY27 Revenue Of A$745-765 Million